Table 1.
Clinical characteristics of patients and diagnostic, procedural and follow up data
| Clinical characteristics |
Angiographic data |
PCI, physiology, IVUS, and follow-up data |
|||
|---|---|---|---|---|---|
| Age (years) | 66 ± 11 | Left anterior descending artery | 16 (52) | Guide wires | 3 [3, 4] |
| Male | 25 (81) | Left circumflex artery | 5 (16) | Lesion length (mm) | 22 [16, 38] |
| Hypertension | 31 (100) | Right coronary artery | 10 (32) | Pre-FFR | 0.74 [0.70, 0.77] |
| Diabetes mellitus | 15 (48) | Proximal reference diameter (mm) | 3.5 [3, 3.5] | Pre-CFR | 1.4 [1.1, 1.9] |
| Current smoking | 0 (0) | Distal reference diameter (mm) | 3 [2.75, 3.5] | Number of stents | 1 [1, 1] |
| Dyslipidaemia | 14 (45) | Diameter stenosis (%) | 80 [70, 90] | Total stent length (mm) | 22 [16, 38] |
| Previous MI | 15 (48) | TIMI 3 flow | 31 (100) | Stent diameter (mm) | 3 [3, 3.5] |
| Previous PCI | 2 (6) | One-vessel disease | 18 (58) | Pre-dilation | 25 (81) |
| Previous CABG | 4 (13) | Two-vessel disease | 8 (26) | Post-dilation | 30 (97) |
| LVEF: | Three-vessel disease | 5 (16) | Minimal stent area (mm2) | 6.8 [5.9, 8.3] | |
| >50% | 21 (68) | Calcified lesions | 22 (71) | Expansion >90% | 27 (87) |
| 35–50% | 4 (13) | ISR | 0 (0) | Post-FFR | 0.92 [0.90, 0.93] |
| <35% | 6 (19) | Syntax score | 12 [8, 19] | Post-CFR | 2.6 [2.3, 4.2] |
| Outpatient medications | |||||
| Aspirin | 28 (90) | ACC/AHA class B2 or C lesions | 13 (42) | Procedure time (min) | 72 [61, 119] |
| Thienopyridine | 15 (48) | Contrast volume (mL) | 13 [12,15] | Fluoroscopy time (min) | 20 [16, 35] |
| Anticoagulant | 2 (6) | Contrast requiring dilution | 8 (26) | Radiation dose (mGy) | 1154 [538, 1932] |
| β-Blocker | 20 (65) | Contrast volume/eGFR | 0.8 [0.6, 0.9] | Follow-up (days) | 79 [33, 207] |
| ACEI/ARB | 9 (29) | Creatinine post angio (mg/dL) | 3.9 [2.9, 4.9] | Follow-up creatinine (mg/dL) | 3.7 [3.0, 4.5] |
| Calcium channel blocker | 22 (71) | Change in creatinine post angio (mg/dL) | 0.1 [0, 0.2] | Change in creatinine (mg/dL) | 0.1 [0.0, 0.4] |
| Nitrate | 8 (26) | eGFR post angio (mL/min/1.73 m2) | 18 ± 8 | Follow-up eGFR (mL/min/1.73 m2) | 18 [14, 22] |
| Statin | 24 (77) | Change in eGFR post angio (mL/min/1.73 m2) | −0.2 [−0.5, 0.5] | Change in eGFR (mL/min/1.73 m2) | −0.2 [−1.4, 1.8] |
| Baseline lab values | |||||
| HbA1C (%) | 6.2 [5.4, 6.7] | Time to measurement of renal function (hours) | 21 [9, 36] | Renal replacement therapy | 0 (0) |
| Creatinine (mg/dL) | 4.2 [3.1, 4.8] | Stent thrombosis | 0 (0) | ||
| eGFR (mL/min/1.73 m2) | 16 ± 8 | Revascularization | 0 (0) | ||
| MI | 0 (0) | ||||
| Death | 0 (0) | ||||
Values are n (%), mean ± SD, and/or median [Q1, Q3].
MI, myocardial infarction; PCI, percutaneous coronary intervention; CABG, coronary artery bypass graft; ACEI/ARB, angiotensin-converting enzyme inhibitor/angiotensin receptor blocker; eGFR, estimated glomerular filtration rate; TIMI, thrombolysis in myocardial infarction; ISR, in-stent restenosis; FFR, fractional flow reserve; CFR, coronary flow reserve.